Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas
Standard
Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. / Hartmann, J T; Oechsle, K; Mayer, F; Kanz, L; Bokemeyer, C.
In: ANTICANCER RES, Vol. 23, No. 2C, 25.06.2003, p. 1899-901.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas
AU - Hartmann, J T
AU - Oechsle, K
AU - Mayer, F
AU - Kanz, L
AU - Bokemeyer, C
PY - 2003/6/25
Y1 - 2003/6/25
N2 - BACKGROUND: The number of cytostatic agents effective in patients with advanced soft tissue sarcoma is limited. Trofosfamide, an alkylating agent, has been shown to be effective in several solid and haematological tumors.PATIENTS AND METHODS: Eighteen patients with a median age of 57 years (range, 27-78) were treated with oral trofosfamide 300 mg/d for 1 week followed by 150 mg/d given continuously to analyze the efficacy and toxicity of continuous low-dose oral trofosfamide. All had received at least one anthracycline-based chemotherapeutic regimen prior to trofosfamide.RESULTS: Nine patients (50%) achieved stable disease lasting for a median of 5.5+ months (range, 1-9+). The median time to progression was 10+ weeks (range, 4-37+) and the median survival 7+ months (range, 2-13+). Toxicity was mild, grade III degree toxicity was seen in 5 patients (28%): 3/2 patients with anemia/neutropenia and 2 patients with fatigue syndrome.CONCLUSION: No objective remission was observed with oral low-dose trofosfamide in heavily pretreated soft tissue sarcoma patients, but almost half of the patients achieved disease stabilisation for half a year. The moderate toxicity profile observed in this study allows the consideration of trofosfamide as a reasonable palliative treatment option for patients with soft tissue sarcoma.
AB - BACKGROUND: The number of cytostatic agents effective in patients with advanced soft tissue sarcoma is limited. Trofosfamide, an alkylating agent, has been shown to be effective in several solid and haematological tumors.PATIENTS AND METHODS: Eighteen patients with a median age of 57 years (range, 27-78) were treated with oral trofosfamide 300 mg/d for 1 week followed by 150 mg/d given continuously to analyze the efficacy and toxicity of continuous low-dose oral trofosfamide. All had received at least one anthracycline-based chemotherapeutic regimen prior to trofosfamide.RESULTS: Nine patients (50%) achieved stable disease lasting for a median of 5.5+ months (range, 1-9+). The median time to progression was 10+ weeks (range, 4-37+) and the median survival 7+ months (range, 2-13+). Toxicity was mild, grade III degree toxicity was seen in 5 patients (28%): 3/2 patients with anemia/neutropenia and 2 patients with fatigue syndrome.CONCLUSION: No objective remission was observed with oral low-dose trofosfamide in heavily pretreated soft tissue sarcoma patients, but almost half of the patients achieved disease stabilisation for half a year. The moderate toxicity profile observed in this study allows the consideration of trofosfamide as a reasonable palliative treatment option for patients with soft tissue sarcoma.
KW - Administration, Oral
KW - Adult
KW - Aged
KW - Antineoplastic Agents, Alkylating
KW - Bone Neoplasms
KW - Cyclophosphamide
KW - Drug Administration Schedule
KW - Humans
KW - Liver Neoplasms
KW - Lung Neoplasms
KW - Lymphatic Metastasis
KW - Middle Aged
KW - Sarcoma
M3 - SCORING: Journal article
C2 - 12820475
VL - 23
SP - 1899
EP - 1901
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 2C
ER -